论文部分内容阅读
目的 探讨153Sm -乙二胺四甲基膦酸 (EDTMP)在恶性肿瘤骨转移患者疼痛治疗中的作用。方法 对伴有剧烈疼痛的 56例多发性骨转移瘤患者 ,采用中国原子能科学研究院同位素所生产的153Sm -EDTMP ,按 37～ 55MBq/Kg一次性静脉注射给药治疗。结果 56例患者中 ,最早在注药后 2d开始疼痛减轻或消失 ,一般为 3～ 13d ,止痛维持时间最长 1年 ,一般 1～ 4个月。疼痛完全消失 (显效 )者占 4 4 .6% ( 2 5/ 56) ;疼痛显著减轻的部分缓解 (好转 )者占 4 2 .9% ( 2 4 / 56) ;无效者占12 .5% ( 7/ 56) ,总有效率为 87.5%。结论 153Sm -EDTMP对恶性肿瘤骨转移产生的剧烈疼痛具有较好的治疗作用 ,而且对转移灶有抑制作用。
Objective To investigate the role of 153Sm - ethylenediaminetetramethylphosphonic acid (EDTMP) in the treatment of pain in patients with malignant bone metastases. Methods Fifty-six patients with multiple bone metastases accompanied by severe pain were treated with 153Sm-EDTMP produced by China Institute of Atomic Energy for 37-55 MBq / Kg intravenously. Results Among the 56 patients, the earliest pain relief or disappearance started 2 days after injection, usually 3 to 13 days, and the longest pain relief time was 1 year, usually 1 to 4 months. Pain disappeared completely (effective) accounted for 44.6% (25/56); pain relief significantly improved partial remission (improved) accounted for 42.9% (24/56); ineffective accounted for 12.5% (7/56), the total effective rate was 87.5%. Conclusion 153Sm-EDTMP has a good therapeutic effect on severe pain caused by bone metastases of malignant tumors, and has an inhibitory effect on metastases.